Evidence map›Paper›PMID 27925847›Full record

ArticleHuman vaccines & immunotherapeutics2017

Effectiveness of hepatitis A vaccination as post-exposure prophylaxis.

Ignasi Parrón, Caritat Planas, Pere Godoy, Sandra Manzanares-Laya, Ana Martínez, Maria Rosa Sala, Sofia Minguell, Nuria Torner, Mireia Jané, Angela Domínguez and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Hepatitis A vaccination.Human vaccines & immunotherapeutics · 2020
    Article
  4. Dating apps and websites as tools to reach anonymous sexual contacts during an outbreak of hepatitis A among men who have sex with men, Berlin, 2017.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2019
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Ignasi Parróna Agència de Salut Pública de Catalunya, Generalitat de Catalunya , Barcelona , Spain.
Caritat Planasa Agència de Salut Pública de Catalunya, Generalitat de Catalunya , Barcelona , Spain.
Pere Godoya Agència de Salut Pública de Catalunya, Generalitat de Catalunya , Barcelona , Spain.
Sandra Manzanares-Layab CIBER Epidemiología y Salud pública (CIBERESP) , Madrid , Spain.
Ana Martíneza Agència de Salut Pública de Catalunya, Generalitat de Catalunya , Barcelona , Spain.
Maria Rosa Salaa Agència de Salut Pública de Catalunya, Generalitat de Catalunya , Barcelona , Spain.
Sofia Minguella Agència de Salut Pública de Catalunya, Generalitat de Catalunya , Barcelona , Spain.
Nuria Tornera Agència de Salut Pública de Catalunya, Generalitat de Catalunya , Barcelona , Spain.
Mireia Janéa Agència de Salut Pública de Catalunya, Generalitat de Catalunya , Barcelona , Spain.
Angela Domínguezb CIBER Epidemiología y Salud pública (CIBERESP) , Madrid , Spain.
Working Group for the Study of Hepatitis A in Catalonia
Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública · ESAgència de Salut Pública de Catalunya · ESGovernment of Catalonia · ESUniversitat de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis A (HA) has been a vaccine-preventable disease since 1995. In Catalonia, a universal combined hepatitis A+B vaccination program of preadolescents was initiated at the end of 1998. However, outbreaks are reported each year and post-exposure prophylaxis (PEP) with hepatitis A virus (HAV) vaccine or immunoglobulin (IG) is recommended to avoid cases. The aim of this study was to assess the effectiveness of HAV vaccine and IG in preventing hepatitis A cases in susceptible exposed people. A retrospective cohort study of contacts of HA cases involved in outbreaks reported in Catalonia between January 2006 and December 2012 was made. The rate ratios and 95% confidence intervals (CI) of HA in susceptible contacts receiving HAV or IG versus those without PEP were calculated. There were 3550 exposed persons in the outbreaks studied: 2381 received one dose of HAV vaccine (Hepatitis A or hepatitis A+B), 190 received IG, and 611 received no PEP. 368 exposed subjects received one dose of HAV vaccine and IG simultaneously and were excluded from the study. The effectiveness of PEP was 97.6% (95% CI 96.2-98.6) for HAV vaccine and 98.3% (95% CI 91.3-99.9) for IG; the differences were not statistically significant (p = 0.36). The elevated effectiveness of HAV vaccination for PEP in HA outbreaks, similar to that of IG, and the long-term protection of active immunization, supports the preferential use of vaccination to avoid secondary cases.

Indexed as

Cost-Benefit AnalysisAdolescentAdultChildChild, PreschoolFemaleHepatitis AHepatitis A VaccinesHumansImmunization, PassiveImmunoglobulins, IntravenousMalePost-Exposure ProphylaxisRetrospective StudiesSpainVaccinationHepatitis A VaccinesImmunoglobulins, IntravenouseffectivenessHepatitis Aimmune globulinoutbreakpost-exposure prophylaxisvaccine

Identifiers

PMID27925847
PMCPMC5328215
OpenAlexW2560092139

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.